Baseline characteristics of patients receiving angiography with continuous DOAC therapy
| Baseline characteristics | |
| Variable | DOAC uninterrupted (n=49) |
| Creatinine (μmol/L) | 87±26.23 |
| eGFR (Cockcroft-Gault) (mL/min) | 75.9±19.3 |
| eGFR ≥60 (%) | 81.6 |
| eGFR 30–59 (%) | 16.3 |
| eGFR <30 (%) | 2 |
| CHAD2S2–VASc score | 2.9±1.6 |
| HAS–BLED score | 1.2±1 |
| ECG atrial fibrillation (paroxysmal or permanent) (%) | 80.4 |
| Medical history | |
| Congestive cardiac failure (%) | 22.4 |
| Controlled hypertension (%) | 59.2 |
| Uncontrolled hypertension (%) | 0 |
| Pulmonary hypertension (%) | 0 |
| Vascular disease (including Ischaemic heart disease) (%) | 32.7 |
| Previous stroke/TIA (%) | 6.1 |
| Venous embolism (%) | 6.1 |
| Mitral or aortic valve disease (%) | 6.1 |
| Aortic stenosis (%) | 6.1 |
| Kidney disease (%) | 10.2 |
| Liver disease (%) | 0 |
| Diabetes mellitus (%) | 6.1 |
| Chronic obstructive pulmonary disease (%) | 2 |
| Hypercholesterolaemia (%) | 30.6 |
| Type of DOAC therapy | |
| Dabigatran (%) | 4.1 |
| Rivaroxaban (%) | 57.1 |
| Apixaban (%) | 32.7 |
| Edoxaban (%) | 6.1 |
| Other medications | |
| Aspirin (%) | 18.4 |
| ADP inhibitor (%) | 6.1 |
| Aspirin with ADP inhibitor (%) | 4.1 |
ADP, adenosine diphosphate; DOAC, direct oral anticoagulant; TIA, transient ischaemic attack; eGFR, estimated glomerular filtration rate.